Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | E7777 |
Synonyms | |
Therapy Description |
E7777 is a recombinant protein consisting of the binding domain of the cytokine IL-2 fused to fragments A and B of the diphtheria toxin, which binds to the IL-2 receptor on tumor cells, and following endocytosis leads to inhibition of protein synthesis, potentially resulting in cell death (PMID: 33792128, NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
E7777 | E-7777|E 7777 | E7777 is a recombinant protein consisting of the binding domain of the cytokine IL-2 fused to fragments A and B of the diphtheria toxin, which binds to the IL-2 receptor on tumor cells, and following endocytosis leads to inhibition of protein synthesis, potentially resulting in cell death (PMID: 33792128, NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01871727 | Phase III | E7777 | A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma | Completed | USA | AUS | 1 |
NCT04855253 | Phase Ib/II | E7777 | Study of E7777 Prior to Kymriah for R/R DLBCL | Recruiting | USA | 0 |